(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/099150 A1

(51) International Patent Classification:
A61K 31/403 (2006.01) *A61P 37/02* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:
PCT/US2021/058483

(22) International Filing Date:
08 November 2021 (08.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/111,312 09 November 2020 (09.11.2020) US

(71) Applicant: **ARENA PHARMACEUTICALS, INC.** [US/US]; 6154 Nancy Ridge Drive, San Diego, California 92121 (US).

(72) Inventors: **FUNG, Maple**; 3992 San Martine Way, San Diego, California 92130 (US). **SELFRIDGE, Andrew Christopher Wesley**; 6154 Nancy Ridge Drive, San Diego, California 92121 (US). **AHLUWALIA, Gurpreet**; 10071 Sunrise Lane, Santa Ana, California 92705 (US).

(74) Agent: **CARTER, Shannon** et al.; Arena Pharmaceuticals, Inc., 6154 Nancy Ridge Drive, San Diego, California 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/099150 A1

(54) Title: METHODS OF TREATING CONDITIONS RELATED TO THE $S1P_1$ RECEPTOR

(57) Abstract: Described herein are methods for treating atopic dermatitis that allows for the effective treatment of the disease with an interruption period if certain adverse events are observed. Additionally, described here are new methods of treating moderate to severe atopic dermatitis.